News Dec 1, 2015 CardioCell Plans Phase IIb Clinical Trial Using Its Stem Cells for Patients With Chronic Heart Failure CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications, intends to proceed with finalizing a
Read MoreCardioCell Plans Phase IIb Clinical Trial Using Its Stem Cells for Patients With Chronic Heart Failure
News Dec 1, 2015 CardioCell Plans Phase IIb Clinical Trial Using Its Stem Cells for Patients With Chronic Heart Failure SAN DIEGO — Dec. 1, 2015 — CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications, intends to
Read MoreCardioCell CEO Presents at the World Congress of Regenerative Medicine & Stem Cell – Shanghai 2015
News Nov 16, 2015 CardioCell CEO Presents at the World Congress of Regenerative Medicine & Stem Cell – Shanghai 2015 SHANGHAI, CHINA – WORLD CONGRESS OF REGENERATIVE MEDICINE & STEM CELL 2015 – Nov. 16, 2015 – CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that
Read More
Journal of the American College of Cardiology
News Nov 3, 2015 Circulation Research, a Journal of the American Heart Association CardioCell's Phase IIa chronic heart failure clinical trial is referenced in a peer-reviewed article now available in the Journal of the American College of Cardiology. The paper illustrates the
Read MoreCardioCell CEO Presents at BIO-Europe 2015
News Oct 28, 2015 CardioCell CEO Presents at BIO-Europe 2015 MUNICH, GERMANY – BIO-EUROPE 2015 – Oct. 28, 2015 – CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications, announces a presentation by CEO Sergey
Read MoreCardioCell Board Members and Clinical Trial Leads Collaborate On Peer-Reviewed Paper Published In The Journal Of Cardiovascular Medicine
News Oct 21, 2015 CardioCell Board Members and Clinical Trial Leads Collaborate On Peer-Reviewed Paper Published In The Journal Of Cardiovascular Medicine CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications,
Read MoreCardioCell Board Members and Clinical Trial Leads Collaborate on Peer-Reviewed Paper Published in the Journal of Cardiovascular Medicine
News Oct 21, 2015 CardioCell Board Members and Clinical Trial Leads Collaborate on Peer-Reviewed Paper Published in the Journal of Cardiovascular Medicine SAN DIEGO — Oct. 21, 2015 — CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for
Read More
Journal of Cardiovascular Medicine
News Oct 21, 2015 Circulation Research, a Journal of the American Heart Association Details from CardioCell's Phase IIa chronic heart failure clinical trial are featured in a peer-reviewed article now available in the Journal of Cardiovascular Medicine. Entitled “Rational and Design
Read More